Influenza, Are You Billing Correctly?

January 31st, 2018 - Chris Woolstenhulme, QCC, CMCS, CPC, CMRS
Categories:   Allergy|Immunology   CPT® Coding   Primary Care|Family Care  
0 Votes - Sign in to vote or comment.

With this year's Flu season being the most widespread on record, providers are seeing more patients and giving more immunizations for influenza than normal. Here are a few things to keep in mind during this flu season. 

Know the rules with your payers to ensure proper reimbursement and correct billing. For example, did you know the Seasonal influenza virus and pneumococcal vaccines and their administration are covered with Part B benefits and not Part D benefits under Medicare?

Medicare will pay for both administration fees for seasonal influenza and pneumococcal vaccines on the same day, report G0009 for Influenza and G0009 for Pneumococcal.   

Other Medicare Tips

  • All physicians, non-physician practitioners (NPPs), and suppliers who administer the seasonal influenza virus and the pneumococcal vaccines must accept assignment on the claims for the vaccines.
  • Enrolled providers may roster bill for seasonal influenza virus and pneumococcal vaccinations even if they are not a mass immunizer.
  • Neither the Part B deductible nor coinsurance or co-payment applies to the seasonal influenza virus, or their administration from physicians or suppliers that agree to accept assignment.
    • A mass immunizer offers influenza virus vaccinations, pneumococcal vaccinations, or both to a group of individuals.
    • Roster billing is a simplified billing process that allows mass immunizers to submit one claim form with a list of several immunized beneficiaries. 
    • Centralized billing allows mass immunizers, who operate in at least three payment localities served by at least three different Medicare Administrative Contractors (MACs), to send all influenza virus and pneumococcal vaccination claims to a designated MAC.

A new code was released in July 2017 for implementation on January 1, 2018, for quadrivalent (ccIIV4).

NEW Code: 90756  Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, IM.   Prior to that HCPCS, Q2039 was used for reporting  Influenza virus vaccine, nos. 

When reporting the encounter be sure to report the correct Z encounter code Z23, encounter for immunization.

Because vaccines are commonly administered at preventative visits you may need to report the E/M code with a modifier 25.   Be sure to verify with the payers you use, to ensure their coding requirements

Administration Codes

90460

 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered

Primary code that can be used with the following Add-on codes-

90461

Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)

Add-on Code, may be used in addition if applicable- Non-Medicare reporting

90472

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition

Add-on Code, may be used in addition if applicable- Non-Medicare reporting

90474

Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Add-on Code, may be used in addition if applicable- Non-Medicare reporting

G0008

Administration of influenza virus vaccine

Medicare requires the use of  a HCPCS code to bill administration for all influenza vaccines

Vaccines

90630

Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use

90645

Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule), for intramuscular use

90646

Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, intramuscular use

90648

Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use

90653

Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use

90654

Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use

90655

Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use

90656

Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use

90657

Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use

90658

Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use

90660

Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use

90661

Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use

90662

Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use

90663

Influenza virus vaccine, pandemic formulation, H1N1

90664

Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use

90666

Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use

90667

Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use

90668

Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use

90672

Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use

90673

Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use

90674

Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use

90682

Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use

90685

Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use

90686

Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use

90687

Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

Things to Consider Before Upgrading Medical Billing Software
August 11th, 2022 - Find-A-Code
Your practice has utilized the same medical billing software for years. The medical billing staff says it is time for a change. You don't necessarily disagree, but you also don't know where to begin your search for new software. There are so many vendors offering so many products that making sense of it all can be challenging.
Calendar Year 2023 Medicare Advantage and Part C & D Payment Policies
August 9th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
Each year CMS publishes an Advance Notice of the upcoming years Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies and asks for comments related to it. Each of the comments are carefully reviewed and responded to and often are impactful to changes seen between the Advance Notice and final publication referred to as the Rate Announcement. With health equity as a primary focus for 2023, CMS announced some policy changes that may impact your organization.
How CMS Determines Which Telehealth Services are Risk Adjustable
August 9th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
Medicare Advantage Organizations (MAOs) have gone back and forth on whether or not to use data collected from telehealth, virtual Care, and telephone (audio-only) encounters with Medicare beneficiaries for risk adjustment reporting, but the following published documents from CMS cleared that up once and for all by providing an answer to a question specifically related to this question.
OIG Investigates SCAN Health for Risk Adjustment Overpayments With Surprising Results
July 26th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
We’ve seen a number of OIG risk adjustment data validation (RADV) audits recently where the independent review contractor was simply looking for any codes the payer reported that were not supported by the documentation, in an effort to declare an overpayment was made and monies are due to be repaid. However, it was refreshing to read this RADV audit and discover that the independent review contractor actually identified HCCs the payer failed to report that, while still resulting in an overpayment, was able to reduce the overpayment by giving credit for these additional HCCs. What lessons are you learning from reading these RADV audit reports?
Addressing Trauma and Mass Violence
July 21st, 2022 - Amanda Ballif
After events of mass violence, it’s easy to feel helpless, like there is little we can do. In fact, we can help individuals, families, and communities build resilience and connect with others to cope together. The SAMHSA-funded National Child Traumatic Stress Network has developed a range of resources to help children, families, educators, and communities including the following which you can access via links in this article.
The 'Big 2' HIPAA Rules Medical Billing Companies Must Follow
July 20th, 2022 - Find-A-Code Staff
HIPAA covers nearly every aspect of how medical and personal information is collected, utilized, shared, and stored within the healthcare industry. Title II of the rules is applied directly to medical billing companies and independent coders. The 'Big 2' rules that medical billing companies must adhere to revolve around privacy and security.
The Beginning of the End of COVID-19-Related Emergency Blanket Waivers
July 19th, 2022 - Aimee L. Wilcox, CPMA, CCS-P, CST, MA, MT
It appears that the end of the 1135 waivers related to the COVID-19 public health emergency (PHE) has begun. According to CMS, the residents of skilled nursing facilities, long-term care facilities, and inpatient hospice centers have struggled due to the effects of some of the 1135 waivers. CMS is focusing primarily on removing the 1135 blanket waivers that pertain to certain aspects of care, training, and maintenance of these facilities to ensure the weakest of our citizens are guaranteed adequate care.



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2022 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association